F2G Revenue
Biotechnology Research • 
Lankro Way, Eccles, United Kingdom • 51-100 Employees
F2G revenue & valuation
| Annual revenue | $110,000,000 |
| Revenue per employee | $1,183,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $352,000,000 |
| Total funding | $170,000,000 |
Company overview
| Headquarters | Lankro Way, Eccles, Manchester, England M30 0LX, GB |
| Phone number | +441617851270 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Employees | 51-100 |
| Socials |
F2G Email Formats
F2G uses 5 email formats. The most common is {first name}{last name} (e.g., johndoe@f2g.com), used 43.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@f2g.com | 43.5% |
{first name}.{last name} | john.doe@f2g.com | 21.7% |
{first initial}{last name} | jdoe@f2g.com | 17.4% |
{first initial}.{first initial}{first initial} | j.jj@f2g.com | 8.7% |
{first initial}.{last name} | j.doe@f2g.com | 4.3% |
About F2G
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
F2G has 24 employees across 11 departments.
Departments
Number of employees
Funding Data
Explore F2G's funding history, including investment rounds, total capital raised, and key backers.
F2G Tech Stack
Discover the technologies and tools that power F2G's digital infrastructure, from frameworks to analytics platforms.
Page builders
WordPress themes
JavaScript libraries
Reverse proxies
Programming languages
Miscellaneous
Blogs
JavaScript libraries
JavaScript libraries
JavaScript libraries
Miscellaneous
Databases
South Africa
Italy
Frequently asked questions
4.8
40,000 users
